기관지천식에서 합성 항혈소판할성인자제들 (Anti - Platelet Activiating Factor Agents)이 혈소판활성인자에 의한 호산구 활성화 및 화학주성능에 미치는 억제능의 비교 연구

다국어 초록 (Multilingual Abstract)

Nowadays because of the role of PAF especially focusing non-specific bronchial hypere- responsiveness(NSBH) which is the fundamental characteristics of asthma, anti PAF agents are under investigation. In this study, the effect of PAF receptor antagonists, structural PAF analogue CV-6209, structurally not related agent WEB 20S6 on PAF-induced eosinophil chemotaxis by Boyden chamber method and activation process, at membrane LTC4 generation and eosinophil cationic pro- tein(ECP) by the process of degranulation by RIA were done. The difference in the potency of both Anti-PAF agents on PAF-induced eosinophil chemotaxis(10^-8M) and the process of activation(10^-7 M) were compared by the subtracted Idgp, concentration producing 50% inhibition, to find the possibility of these agents as anti-asthmatics. The results were as follows - 1) Idgp of CV, WEB on eosinophil chemotaxis were 1.32+-0,43X10^-7, 1.87+-0.56X10^-7 respectively. 2) Idgp on LTC production of CV, WEB, were 1.38+-0.36X10^-5 , 1.36+-0.54X10^-5 and these were less potent than chemotaxis (P = 0.024). 3) ID50 on ECP release of CV, WEB were 3.2 +- 0.56X10^-6 , 1.6 +- 0.32X10^-6 ', and also less potent than chemotaxis(P=0.037). From these results we documented PAF infiltrated and activated eosinophil in vitro, and also PAF receptor antagonist, CV-6209, WEB 2086 inhibited PAF- induced not only eosinophol chemotaxis but activation. We speculate these agent might inhibit NSBR through these actions in vivo and in near future we expect these agents clinical trial as anti-asthma drug.